Background:
The objective of this study is to estimate the causal
relationship between plasma proteins and myocardial infarction (MI) through
Mendelian randomization (MR), predict potential target-mediated side effects
associated with protein interventions, and ensure a comprehensive assessment of
clinical safety.
Methods:
From 3 proteome genome-wide association
studies (GWASs) involving 9775 European participants, 331 unique blood proteins
were screened and chosed. The summary data related to MI were derived from a GWAS
meta-analysis, incorporating approximately 61,000 cases and 577,000 controls. The
assessment of associations between blood proteins and MI was conducted through MR
analyses. A phenome-wide MR (Phe-MR) analysis was subsequently employed to
determine the potential on-target side effects of protein interventions.
Results:
Causal mediators for MI were identified, encompassing
cardiotrophin-1 (CT-1) (odds ratio [OR] per SD increase: 1.16; 95% confidence
interval [CI]: 1.13–1.18;
p
= 1.29
),
Selenoprotein S (SELENOS) (OR: 1.16; 95% CI: 1.13–1.20;
p
= 4.73
), killer cell immunoglobulin-like receptor 2DS2 (KIR2DS2)
(OR: 0.93; 95% CI: 0.90–0.96;
p
= 1.08
), vacuolar
protein sorting-associated protein 29 (VPS29) (OR: 0.92; 95% CI: 0.90–0.94;
p
= 8.05
), and histo-blood group ABO system
transferase (NAGAT) (OR: 1.05; 95% CI: 1.03–1.07;
p
= 1.41
). In the Phe-MR analysis, memory loss risk was mediated by CT-1, VPS29
exhibited favorable effects on the risk of 5 diseases, and KIR2DS2 showed no
predicted detrimental side effects.
Conclusions:
Elevated genetic
predictions of KIR2DS2 and VPS29 appear to be linked to a reduced risk of MI,
whereas an increased risk is associated with CT-1, SELENOS, and NAGAT. The
characterization of side effect profiles aids in the prioritization of drug
targets. Notably, KIR2DS2 emerges as a potentially promising target for
preventing and treating MI, devoid of predicted detrimental side effects.